



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

May 11, 2021

Richard Murray, Ph.D.
President and Chief Executive Officer
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139

Re: Jounce Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 4, 2021
File No. 333-255760

Dear Dr. Murray:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jeffrey Gabor at 202-551-2544 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Rosemary G. Reilly, Esq.